Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | RXRA | P19793 | 7/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 7/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 7/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2794945 | 0.84 | ALDH1A1 (0.38) | ALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL15197105 | 0.82 | CSNK2A1 (0.33) | ALDH1A1MEN1KMT2A | |
| SCHEMBL266161 | 0.81 | PDE4A (0.38) | ALDH1A1MEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL31098670 | 0.81 | PDE4A (0.38) | ALDH1A1MEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL10821843 | 0.79 | ALDH1A1 (0.46) | ALDH1A1MEN1MAPTKMT2ARXRA | |
| SCHEMBL12180428 | 0.78 | MEN1 (0.44) | ALDH1A1MEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL900859 | 0.78 | ALDH1A1 (0.39) | ALDH1A1MEN1MAPTKMT2ARXRA | |
| SCHEMBL12548655 | 0.78 | GRIN2B (0.37) | ALDH1A1MAPTKMT2ARXRAGRIN1 | |
| SCHEMBL28651200 | 0.77 | PDE4A (0.35) | ALDH1A1SMN1; SMN2LMNASLC6A4 | |
| SCHEMBL28437121 | 0.76 | SLC6A2 (0.35) | MEN1KMT2ASMN1; SMN2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895552-B2 | Cyclic amide derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-20130217692-A1 | CYCLIC AMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-08-22 | — | — | US | disclosed |
| US-8133909-B2 | Heteroaromatic monoamides as orexinin receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-03-13 | — | — | US | disclosed |
| EP-2297102-A1 | HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2011-03-23 | — | — | EP | disclosed |
| WO-2009153180-A1 | HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-23 | — | — | WO | disclosed |
| US-20090312314-A1 | HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312314-A1 | HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPSR1 | ALDH1A1 1706/4885MEN1 1019/4885MAPT 2689/4885 |
| US-20130217692-A1 | CYCLIC AMIDE DERIVATIVE | HDAC10, H1-10, H1-0 | ALDH1A1 538/4885MEN1 325/4885MAPT 3973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.